NCT00326885 2018-10-17Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant AscitesNeovii BiotechPhase 2 Completed32 enrolled 12 charts
NCT00377429 2012-07-19Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to ChemotherapyNeovii BiotechPhase 2 Completed47 enrolled 11 charts